Mallinckrodt Announces Interim Analysis Results for Therakos(R...
STAINES-UPON-THAMES, United Kingdom, Feb. 21, 2019 /PRNewswire-AsiaNet/ -- -- Overall response rate exceeded specified study midpoint target (n=25); company elects to discontinue further patient enrollment as allowed by protocol --Mallinckrodt plc (NYSE:MNK), a leading global specialty pharmaceutical company, today a...
Authors: LATEST ASIANET NEWS RELEASES